Compare DexCom, Inc. (DXCM) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Funko Inc — how do they compare? DexCom, Inc. trades at $76.89 (market cap $28.06B), while Funko Inc trades at $5.74 (market cap $315.21M). The key difference: DexCom, Inc. is far larger — about 89× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | FNKO | |
|---|---|---|
Market Cap | $28.06B | $315.21M |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $5.88 |
52-Week Low | $54.84 | $2.46 |
Enterprise Value | $27.03B | $560.25M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
FNKO trades at $5.785, up 4.23% today, with a bullish technical signal from moving averages. The stock shows improving revenue trends, with Q1 2026 sales reaching $200.9M, beating expectations, though net income remains negative. Analyst consensus is split between Buy and Hold, with no Sell ratings. Recent news highlights new product launches and strong collectibles demand, supporting a positive sentiment shift.
Outlook: FNKO presents a speculative opportunity with recent earnings beats and revenue growth, but risks include persistent net losses and high debt. Investors should weigh the bullish technicals and product momentum against fundamental weaknesses in profitability and cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
